Closing the gap in osteoporosis management: the critical role of primary care in bone health

References

• Jakab M, Farrington J, Borgermans L, et al. Health systems respond to noncommunicable diseases: time for ambition. World Health Organization. Regional Office for Europe; 2018 [cited 2022 Jul 22]. https://www.who.int/europe/publications/i/item/9789289053402
   Google Scholar
• International Osteoporosis Foundation. Facts and statistics. Epidemiology of osteoporosis and fragility fractures. [cited 2022 July 22]. https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures
   Google Scholar
• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–795.
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2020;26(Suppl 1):1–46.
   PubMed Web of Science ®Google Scholar
• LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049–2102.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.
   PubMed Web of Science ®Google Scholar
• Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020;105(3):dgaa048.
   PubMed Web of Science ®Google Scholar
• Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 2021. 28(9):973–997.
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation and Bone Health & Osteoporosis Foundation. Osteoporosis and fracture risk evaluation. A tool for primary care providers (US version). [cited 2022 Jul 22]. http://www.bonehealthandosteoporosis.org/wp-content/uploads/Radically-Simple-Tool_BHOF.pdf
   Google Scholar
• International Osteoporosis Foundation and Bone Health & Osteoporosis Foundation. Osteoporosis and fracture risk evaluation. A tool for primary care physicians to share with patients (UK version). [cited 2022 Jul 22]. https://www.osteoporosis.foundation/sites/iofbonehealth/files/2022-06/RadicallySimpleTest_IOF_EN_0.pdf
   Google Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–1733.
   PubMed Web of Science ®Google Scholar
• GBD 2019 Fracture Collaborators. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2021;2:e580–e592.
   PubMedGoogle Scholar
• Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741–747.
   PubMed Web of Science ®Google Scholar
• Bone Health and Osteoporosis Foundation. National Bone Health Policy Institute. Facts about bone health. [cited 2022 Jul 22]. https://www.bonehealthpolicyinstitute.org/bone-facts
   Google Scholar
• Hansen D, Pelizzari P, Pyenson B. Medicare cost of osteoporotic fractures - 2021 updated report: the clinical and cost burden of fractures associated with osteoporosis. March 2021. Commissioned by the National Osteoporosis Foundation. [cited 2022 Jul 22]. https://www.milliman.com/en/insight/-/media/milliman/pdfs/2021-articles/3-30-21-Medicare-Cost-Osteoporotic-Fractures.ashx
   Google Scholar
• Tajeu GS, Delzell E, Smith W, et al. Death, debility, and destitution following hip fracture. J Gerontol A Biol Sci Med Sci. 2014;69(3):346–353.
   PubMed Web of Science ®Google Scholar
• Tarride J-E, Hopkins RB, Leslie WD, et al. The burden of illness of osteoporosis in Canada. Osteoporos Int. 2012;23(11):2591–2600.
   PubMed Web of Science ®Google Scholar
• Xie Z, Burge R, Yang Y, et al. Posthospital discharge medical care costs and family burden associated with osteoporotic fracture patients in China from 2011 to 2013. J Osteoporos. 2015;2015:258089.
   PubMedGoogle Scholar
• National Osteoporosis Society. Life with osteoporosis: the untold story. [cited 2022 Jul 22]. https://alterlinehealth.co.uk/wp-content/uploads/2014/10/NOS-Life-with-Osteoporosis-the-untold-story-Alterline.pdf
   Google Scholar
• Singer A, Exuzides A, Spangler L, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015;90(1):53–62.
   PubMed Web of Science ®Google Scholar
• Sernbo I, Johnell O. Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int. 1993;3(3):148–153.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J, et al. Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. JBMR Plus. 2019;3(9):e10192.
   PubMedGoogle Scholar
• Borgström F, Karlsson L, Ortsäter G, et al. Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 2020;15(1):59.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Norton N, Harvey NC, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16(1):82.
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation. IOF compendium of osteoporosis. [cited 2022 Jul 22]. http://share.iofbonehealth.org/WOD/Compendium/2019-IOF-Compendium-of-Osteoporosis-PRESS.pdf
   Google Scholar
• Willers C, Norton N, Harvey NC, et al. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022;17(1):23.
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation. Capture the fracture. [cited 2022 Jul 22]. https://www.capturethefracture.org/faq
   Google Scholar
• Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7(5):407–413.
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust. 2004;180(S5):S18–S22.
   PubMed Web of Science ®Google Scholar
• Yusuf AA, Matlon TJ, Grauer A, et al. Utilization of osteoporosis medication after a fragility fracture among elderly medicare beneficiaries. Arch Osteoporos. 2016;11(1):31.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Yu O, Balasubramanian A, et al. A survey of women’s awareness of and reasons for lack of postfracture osteoporotic care. J Am Geriatr Soc. 2017;65(8):1829–1835.
   PubMed Web of Science ®Google Scholar
• Sale JEM, Beaton D, Posen J, et al. Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. Osteoporos Int. 2011;22(7):2067–2082.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929–1937.
   PubMed Web of Science ®Google Scholar
• Rabenda V, Reginster J-Y. Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):677–689.
   PubMed Web of Science ®Google Scholar
• Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493–1501.
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57.
   PubMed Web of Science ®Google Scholar
• Willson T, Nelson SD, Newbold J, et al. The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol. 2015;7:65–76.
   PubMed Web of Science ®Google Scholar
• Weaver CM, Gordon CM, Janz KF, et al. The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int. 2016;27(4):1281–1386.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Cawthon PM, Peters KE, et al. Risk factors for hip fracture in older men: the Osteoporotic Fractures in Men Study (MrOS). J Bone Miner Res. 2016;31(10):1810–1819.
   PubMed Web of Science ®Google Scholar
• Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297(4):387–394.
   PubMed Web of Science ®Google Scholar
• Balasubramanian A, Zhang J, Chen L, et al. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. 2019;30(1):79–92.
   PubMed Web of Science ®Google Scholar
• Johansson H, Siggeirsdóttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28(3):775–780.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12.
   PubMed Web of Science ®Google Scholar
• van Geel TACM, van Helden S, Geusens PP, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68(1):99–102.
   PubMed Web of Science ®Google Scholar
• Conley RB, Adib G, Adler RA, et al. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res. 2020;35(1):36–52.
   PubMed Web of Science ®Google Scholar
• Weaver J, Sajjan S, Lewiecki EM, et al. Prevalence and cost of subsequent fractures among U.S. patients with an incident fracture. J Manag Care Spec Pharm. 2017;23(4):461–471.
   PubMedGoogle Scholar
• Gillespie CW, Morin PE. Trends and disparities in osteoporosis screening among women in the United States, 2008–2014. Am J Med. 2017;130(3):306–316.
   PubMed Web of Science ®Google Scholar
• Ganda K, Mitchell PJ, Seibel MJ. Chapter 3 - models of secondary fracture prevention: systematic review and metaanalysis of outcomes. In: Seibel MJ, Mitchell PJ, editors. Secondary fracture prevention: an international perspective. London: Academic Press; 2019. p. 33–62.
   Google Scholar
• Grigoryan KV, Javedan H, Rudolph JL. Orthogeriatric care models and outcomes in hip fracture patients: a systematic review and meta-analysis. J Orthop Trauma. 2014;28(3):e49–e55.
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation. Capture the fracture map of best practice. [cited 2022 Jul 22]. http://capturethefracture.org/map-of-best-practice
   Google Scholar
• Greenspan SL, Singer A, Vujevich K, et al. Implementing a fracture liaison service open model of care utilizing a cloud-based tool. Osteoporos Int. 2018;29(4):953–960.
   PubMed Web of Science ®Google Scholar
• Ganda K, Puech M, Chen JS, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int. 2013;24(2):393–406.
   PubMed Web of Science ®Google Scholar
• Li N, van Oostwaard M, van den Bergh JP, et al. Health-related quality of life of patients with a recent fracture attending a fracture liaison service: a 3-year follow-up study. Osteoporos Int. 2022;33(3):577–588.
   PubMed Web of Science ®Google Scholar
• Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1999;14(5):821–828.
   PubMed Web of Science ®Google Scholar
• Gehlbach S, Saag KG, Adachi JD, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the global longitudinal study of osteoporosis in women. J Bone Miner Res. 2012;27(3):645–653.
   PubMed Web of Science ®Google Scholar
• Colón-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003;14(11):879–883.
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Odén A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15(3):175–179.
   PubMedGoogle Scholar
• International Society for Clinical Densitometry. 2019. ISCD official positions: adult. [cited 2022 Jul 22]. https://iscd.org/learn/official-positions/adult-positions/
   Google Scholar
• Curry SJ, Krist AH, Owens DK, et al. Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement. JAMA. 2018;319(24):2521–2531.
   PubMed Web of Science ®Google Scholar
• Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008;358(14):1474–1482.
   PubMed Web of Science ®Google Scholar
• Szulc P, Delmas PD. Biochemical markers of bone turnover in men. Calcif Tissue Int. 2001;69(4):229–234.
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Guideline Group. NOGG 2021: Clinical guideline for the prevention and treatment of osteoporosis. [cited 2022 Jul 22]. https://www.nogg.org.uk/full-guideline
   Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes–2020. Diabetes Care. 2020;43(Suppl 1):S66–S76. [cited 2022 Jul 22]. https://care.diabetesjournals.org/content/43/Supplement_1/S66
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e563–e595.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Lin JS, Mustafa RA, et al. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Ann Intern Med. 2019;170(8):547–560.
   PubMed Web of Science ®Google Scholar
• Siris ES, Chen Y-T, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108–1112.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines) for non-small cell lung cancer V1.2022. [cited 2022 June 13]. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622.
   PubMed Web of Science ®Google Scholar
• Roux C, Briot K. Imminent fracture risk. Osteoporos Int. 2017;28(6):1765–1769.
   PubMed Web of Science ®Google Scholar
• Fosamax (alendronate sodium) prescribing information, Merck & Co. 1995. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020560s068,021575s024lbl.pdf
   Google Scholar
• Boniva (ibandronate sodium) prescribing information, Genentech 2003. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021455s009lbl.pdf
   Google Scholar
• Actonel (risedronate sodium) prescribing information, Allergan 1998. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf
   Google Scholar
• Reclast (zoledronic acid) prescribing information, Novartis 2001. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021817s027lbl.pdf
   Google Scholar
• Prolia (denosumab) prescribing information, Amgen Inc. 2010. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0000lbl.pdf
   Google Scholar
• Evista (raloxifene hydrochloride) prescribing information, Eli Lilly & Company 1997. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022042lbl.pdf
   Google Scholar
• Forteo (teriparatide) prescribing information, Eli Lilly & Company 1987. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021318s053lbl.pdf
   Google Scholar
• Tymlos (abaloparatide) prescribing information, Radius Health 2017. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf
   Google Scholar
• Evenity (romosozumab-aqqg) prescribing information, Amgen Inc. 2019. [cited 22 Jul 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf
   Google Scholar
• Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017;32(2):198–202.
   PubMed Web of Science ®Google Scholar
• Cosman F. Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture. Endocr Pract. 2020;26(7):777–786.
   PubMed Web of Science ®Google Scholar
• Curtis EM, Reginster JY, Al-Daghri N, et al. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res. 2022;34(4):695–714.
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523.
   PubMed Web of Science ®Google Scholar
• Brown JP, Roux C, Törring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746–752.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–198.
   PubMed Web of Science ®Google Scholar
• McClung MR, Wagman RB, Miller PD, et al. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28(5):1723–1732.
   PubMed Web of Science ®Google Scholar
• Lamy O, Gonzalez-Rodriguez E, Stoll D, et al. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 2017;102(2):354–358.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–1543.
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427.
   PubMed Web of Science ®Google Scholar
• Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17(1):58.
   PubMed Web of Science ®Google Scholar
• McClung MR, Rothman MS, Lewiecki EM, et al. The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med. 2022;134(6):541–551.
   PubMed Web of Science ®Google Scholar
• Thomas T, Casado E, Geusens P, et al. Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of european experts. Osteoporos Int. 2020;31(12):2303–2311.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Cosman F, Lewiecki EM, et al. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res. 2017;32(1):3–10.
   PubMed Web of Science ®Google Scholar
• Joint guidance on osteoporosis management in the era of COVID-19 from the American Society for Bone and Mineral Research (ASBMR), American Association of Clinical Endocrinologists (AACE), Endocrine Society, European Calcified Tissue Society (ECTS) and National Osteoporosis Foundation (NOF) [published 2020 May 7; cited 2022 Jul 22]. https://www.endocrine.org/-/media/endocrine/files/membership/joint-statement-on-covid19-and-osteoporosis-final.pdf
   Google Scholar
• Joint guidance on COVID-19 vaccination and osteoporosis management from the ASBMR, AACE, ECTS, IOF, and NOF [published 2021 Mar 9; cited 2022 Jul 22]. https://www.asbmr.org/about/statement-detail/joint-guidance-on-covid-19-vaccine-osteoporosis
   Google Scholar
• Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623–1630.
   PubMed Web of Science ®Google Scholar
• Chesnut CH, IIISkag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–1249.
   PubMed Web of Science ®Google Scholar
• Hall SF, Edmonds SW, Lou Y, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003). 2017;57(4):503–509.
   PubMed Web of Science ®Google Scholar
• Liu J, Guo H, Rai P, et al. Medication persistence and risk of fracture among female medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int. 2018;29(11):2409–2417.
   PubMed Web of Science ®Google Scholar
• Sunyecz JA, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int. 2008;19(10):1421–1429.
   PubMed Web of Science ®Google Scholar
• Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int. 2009;20(12):2127–2134.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Salas M, Hughes DA, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR medication adherence & persistence special interest group. Osteoporos Int. 2013;24(12):2907–2918.
   PubMed Web of Science ®Google Scholar
• Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int. 2011;22(3):741–753.
   PubMed Web of Science ®Google Scholar